Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atropine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 1.00 |
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 4/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hyoscyamine SCHEMBL41316 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL41317 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL17775090 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL14946873 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL8854381 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL7941966 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL25020 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL2812 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL249586 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Hyoscyamine SCHEMBL4957671 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012056452-A2 | PHARMACEUTICAL COMPOSITIONS AND DELIVERY DEVICES COMPRISING STINGING CELLS OR CAPSULES | NANOCYTE (ISRAEL) LTD. (IL) | 2012-05-03 | — | — | WO | claimed |
| CN-103717597-B | Heterocyclic compounds as kinase inhibitors | 原真股份有限公司 | 2017-07-04 | — | — | CN | disclosed |
| CN-103492389-B | Pyrazolo [4,3-d] pyrimidine as inhibitors of kinases | 原真股份有限公司 | 2016-09-14 | — | — | CN | disclosed |
| US-20150250714-A1 | PHARMACEUTICAL COMPOSITIONS AND DELIVERY DEVICES COMPRISING STINGING CELLS OR CAPSULES | NANOCYTE (ISRAEL) LTD. (IL) | 2015-09-10 | — | — | US | disclosed |
| US-20130216603-A1 | PHARMACEUTICAL COMPOSITIONS AND DELIVERY DEVICES COMPRISING STINGING CELLS OR CAPSULES | NANOCYTE (ISRAEL) LTD. (IL) | 2013-08-22 | — | — | US | disclosed |
| WO-2012056452-A2 | PHARMACEUTICAL COMPOSITIONS AND DELIVERY DEVICES COMPRISING STINGING CELLS OR CAPSULES | NANOCYTE (ISRAEL) LTD. (IL) | 2012-05-03 | — | — | WO | disclosed |
| EP-1549302-A1 | GASTROINTESTINAL COMPOSITIONS COMPRISING GABA DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | disclosed |
| EP-1531801-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OR MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004006902-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OR MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006901-A1 | GASTROINTESTINAL COMPOSITIONS COMPRISING GABA DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| US-5932240-A | Multidose transdermal drug delivery system | AMERICARE TECHNOLOGY, INC. (US) | 1999-08-03 | — | — | US | disclosed |
| US-5756117-A | LAMINATE COMPOSITE WITH A PLURALITY OF COMPARTMENTS, EACH A RESERVOIR FOR A UNIT DOSE OF A DRUG; INDIVIDUAL REMOVABLE SEALS TO RELEASE DOSE INTO CONTACT WITH SKIN | INTERNATIONAL MEDICAL ASSCOCIATES, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| US-5505957-A | Selectable dosage transdermal delivery system | INTERNATIONAL MEDICAL ASSOCIATES, INC. (US) | 1996-04-09 | — | — | US | disclosed |
| US-5336213-A | Selectable dosage transdermal delivery system | INTERNATIONAL MEDICAL ASSOCIATES, INC. (US) | 1994-08-09 | — | — | US | disclosed |